Experience in production of 68Ga-DOTA-NOC for clinical use under an Expanded Access IND

Mark Green, Carla J. Mathias, James Fletcher

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

[68Ga]Ga-DOTA-NOC was produced under an Expanded Access IND for 174 clinical PET/CT studies to evaluate patients with neuroendocrine tumors. Production employed either the TiO2-based Eckert & Ziegler (EZAG) 68Ge/68Ga-generator (with fractionated elution), or the SiO2-based ITG 68Ge/68Ga-generator. In both cases, [68Ga]Ga-DOTA-NOC was reliably produced, without pre-synthesis purification of the 68Ga generator eluate, using readily-implemented manual synthesis procedures. [68Ga]Ga-DOTA-NOC radiochemical purity averaged 99.2±0.4%. Administered 68Ga dose averaged 181±22 MBq, and administered peptide mass averaged 43.2±5.2 µg (n=47) and 23.9±5.7 µg (n=127), respectively, using the EZAG and ITG generators. At dose expiration, 68Ge breakthrough in the final product averaged 2.7×10−7% and 5.4×10−5% using the EZAG and ITG generators, respectively.

Original languageEnglish (US)
Pages (from-to)63-68
Number of pages6
JournalApplied Radiation and Isotopes
Volume116
DOIs
StatePublished - Oct 1 2016

Fingerprint

generators
expiration
dosage
elution
synthesis
purification
peptides
purity
tumors
products

Keywords

  • Expanded Access IND
  • Neuroendrocrine tumors
  • Positron emission tomography (PET)
  • Somatostatin receptor
  • [68Ga]Ga-DOTA-NOC

ASJC Scopus subject areas

  • Radiation

Cite this

Experience in production of 68Ga-DOTA-NOC for clinical use under an Expanded Access IND. / Green, Mark; Mathias, Carla J.; Fletcher, James.

In: Applied Radiation and Isotopes, Vol. 116, 01.10.2016, p. 63-68.

Research output: Contribution to journalArticle

@article{5764729a7beb411d9ecb5c4c0c57fc70,
title = "Experience in production of 68Ga-DOTA-NOC for clinical use under an Expanded Access IND",
abstract = "[68Ga]Ga-DOTA-NOC was produced under an Expanded Access IND for 174 clinical PET/CT studies to evaluate patients with neuroendocrine tumors. Production employed either the TiO2-based Eckert & Ziegler (EZAG) 68Ge/68Ga-generator (with fractionated elution), or the SiO2-based ITG 68Ge/68Ga-generator. In both cases, [68Ga]Ga-DOTA-NOC was reliably produced, without pre-synthesis purification of the 68Ga generator eluate, using readily-implemented manual synthesis procedures. [68Ga]Ga-DOTA-NOC radiochemical purity averaged 99.2±0.4{\%}. Administered 68Ga dose averaged 181±22 MBq, and administered peptide mass averaged 43.2±5.2 µg (n=47) and 23.9±5.7 µg (n=127), respectively, using the EZAG and ITG generators. At dose expiration, 68Ge breakthrough in the final product averaged 2.7×10−7{\%} and 5.4×10−5{\%} using the EZAG and ITG generators, respectively.",
keywords = "Expanded Access IND, Neuroendrocrine tumors, Positron emission tomography (PET), Somatostatin receptor, [68Ga]Ga-DOTA-NOC",
author = "Mark Green and Mathias, {Carla J.} and James Fletcher",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.apradiso.2016.07.010",
language = "English (US)",
volume = "116",
pages = "63--68",
journal = "Applied Radiation and Isotopes",
issn = "0969-8043",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Experience in production of 68Ga-DOTA-NOC for clinical use under an Expanded Access IND

AU - Green, Mark

AU - Mathias, Carla J.

AU - Fletcher, James

PY - 2016/10/1

Y1 - 2016/10/1

N2 - [68Ga]Ga-DOTA-NOC was produced under an Expanded Access IND for 174 clinical PET/CT studies to evaluate patients with neuroendocrine tumors. Production employed either the TiO2-based Eckert & Ziegler (EZAG) 68Ge/68Ga-generator (with fractionated elution), or the SiO2-based ITG 68Ge/68Ga-generator. In both cases, [68Ga]Ga-DOTA-NOC was reliably produced, without pre-synthesis purification of the 68Ga generator eluate, using readily-implemented manual synthesis procedures. [68Ga]Ga-DOTA-NOC radiochemical purity averaged 99.2±0.4%. Administered 68Ga dose averaged 181±22 MBq, and administered peptide mass averaged 43.2±5.2 µg (n=47) and 23.9±5.7 µg (n=127), respectively, using the EZAG and ITG generators. At dose expiration, 68Ge breakthrough in the final product averaged 2.7×10−7% and 5.4×10−5% using the EZAG and ITG generators, respectively.

AB - [68Ga]Ga-DOTA-NOC was produced under an Expanded Access IND for 174 clinical PET/CT studies to evaluate patients with neuroendocrine tumors. Production employed either the TiO2-based Eckert & Ziegler (EZAG) 68Ge/68Ga-generator (with fractionated elution), or the SiO2-based ITG 68Ge/68Ga-generator. In both cases, [68Ga]Ga-DOTA-NOC was reliably produced, without pre-synthesis purification of the 68Ga generator eluate, using readily-implemented manual synthesis procedures. [68Ga]Ga-DOTA-NOC radiochemical purity averaged 99.2±0.4%. Administered 68Ga dose averaged 181±22 MBq, and administered peptide mass averaged 43.2±5.2 µg (n=47) and 23.9±5.7 µg (n=127), respectively, using the EZAG and ITG generators. At dose expiration, 68Ge breakthrough in the final product averaged 2.7×10−7% and 5.4×10−5% using the EZAG and ITG generators, respectively.

KW - Expanded Access IND

KW - Neuroendrocrine tumors

KW - Positron emission tomography (PET)

KW - Somatostatin receptor

KW - [68Ga]Ga-DOTA-NOC

UR - http://www.scopus.com/inward/record.url?scp=84982683677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982683677&partnerID=8YFLogxK

U2 - 10.1016/j.apradiso.2016.07.010

DO - 10.1016/j.apradiso.2016.07.010

M3 - Article

AN - SCOPUS:84982683677

VL - 116

SP - 63

EP - 68

JO - Applied Radiation and Isotopes

JF - Applied Radiation and Isotopes

SN - 0969-8043

ER -